title: DNA damage, tumor mutational load and their impact on immune responses against cancer.
abstract: Advances in immunotherapy have changed the therapeutic landscape in many malignancies. Immune checkpoint inhibitors have already received regulatory approval in melanomas, lung, renal and bladder carcinomas. A common feature of these neoplasms is the increased mutational load, related to a possible increase number of tumor neoantigens that are recognized by the immune system. The mechanisms that DNA damage could confer to the mutational load and the formation of neoantigens and how this could be exploited to advance our immunotherapeutic strategies is discussed in this review.
authors: Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece ;
authors: Michalis
authors: M
authors: Liontos
authors: 1 Department of Urology, Laiko Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
authors: Ioannis
authors: I
authors: Anastasiou
authors: Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece ;
authors: Aristotelis
authors: A
authors: Bamias
authors: Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece ;
authors: Meletios-Athanasios
authors: MA
authors: Dimopoulos
keywords: DNA damage; cancer; immunotherapy; mutational load